Summary
There is evidence suggesting limited use of the NBOMe class of drugs as novel psychoactive substances compared with that of classical recreational drugs and other novel psychoactive substances such as mephedrone.
Main navigation
-
Data
Open related submenu
Data
Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
Latest data
-
Countries
Open related submenu
Countries
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
-
Topics
Open related submenu
Selected topics
-
Best practice
Open related submenu
Best practice
The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses.
In this section
-
Activities
Open related submenu
Activities
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
Selected areas
-
Publications
Open related submenu
Publications
Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it.
In this section
Featured publications
Recently published
-
Events
Open related submenu
-
News
Open related submenu
-
About
Open related submenu
About the EUDA
We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations.
In this section